IGBA letter to FDA regarding their biologics naming proposals
The International Generic and Biosimilar Medicines Association (IGBA), representing member associations from the U.S. (GPhA), Canada (CGPA), Japan (JGA), Jordan (JAPM), Europe (EGA), South Africa (NAPM), and Taiwan (TGPA), as well as associate member associations from Australia (GBMA), Brazil (ProGenericos) and Mexico (AMEGI), thank for the opportunity to share our thoughts on the important topic of non-proprietary naming of biological products, including biosimilar products.